Pharmaceuticals

Moderna and Merck Announce Promising Trial Data for V940 in Combination with Keytruda in Treating High-Risk Melanoma After Complete Resectomy

bexib
By bexib 0 Min Read

After a three-year study, the combination of V940 and Keytruda demonstrated a durable benefit in recurrence-free and distant metastasis-free survival in patients with high-risk melanoma after complete resection.

You Might Also Like

FDA approves Servier’s Voranigo for grade 2 IDH-mutated glioma

Johnson & Johnson Submits Supplemental New Drug Application to FDA for Spravato as Monotherapy for Adults with Treatment-Resistant Depression

InvoX Pharma’s FS222 shows promising results in the treatment of solid tumors

Pharma Pulse 7/2/24: Employers maintain benefits despite rising costs, Amazon invests in AI future, and more

Lilly’s admissions commissioner’s victory suggests amyloid and tau likely dominate Alzheimer’s — for now

Share This Article
Previous Article Job openings fell to 8.1 million in April
Next Article Tissue testing for higher yields – RealAgriculture
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Late onboarding promotes clients’ losses at Singapore banks.
Fintech
The gorgeous spa Hotelgal Goma Resort will join the elegant hotel collection as the first member of the North Ireland
Hospitality & Tourism
Peter Navalo says, necessary for Trump’s economic success vision
Manufacturing
What you need to know about Singapore’s most common payment fraud
Fintech